Evidence map›Paper›PMID 37485262›Full record

ArticleFrontiers in cardiovascular medicine2023

Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up.

Abdurashid Mussayev, Serik Alimbayev, Nursultan Tanaliev, Aidyn Kuanyshbek, Aripov Marat, Timur Lesbekov, Yerkezhan Raissov, Aigerim Sadykova, Askarovna Kenzhebayeva Kamila, Murat Mukarov and 1 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Abdurashid MussayevHead of Cathlab, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Serik AlimbayevHead of Structural Heart Diseases, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Nursultan TanalievDepartment of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Aidyn KuanyshbekHead of the Department of Anesthesiology, Resuscitation and Intensive Care, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Aripov MaratHead of Department of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Timur LesbekovHead of the Department of Cardiac Surgery, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Yerkezhan RaissovResident of Interventional Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Aigerim SadykovaChief Nurse of Cathlab, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Askarovna Kenzhebayeva KamilaClinical Cardiologist, Central Hospital with a Polyclinic of the Ministry of Internal Affairs, Astana, Republic of Kazakhstan.
Murat MukarovHead of the Department of Cardiology, National Research Cardiac Surgery Center, Astana, Kazakhstan.
Yuriy PyaDepartment of Cardiac Surgery, National Research Cardiac Surgery Center, Astana, Kazakhstan.
National Research Center for Maternal and Child Health · KZAstana Medical University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Generally, the dysfunction or failure of bioprosthetic heart valves (BHVs) is managed by replacement surgery. In the case of tricuspid valve dysfunction, re-do surgery is rarely attempted because of the critically high risk of developing pulmonary hypertension, pulmonary embolism, and intraoperative mortality. Hence, transcatheter tricuspid repair and replacement procedures are preferred. More recently, transcatheter valve-in-valve (ViV) treatments have gained importance because of their less invasiveness, especially for patients with prior surgeries. Encouraging evidence of the safety and effectiveness of a novel balloon-expandable (BE) transcatheter heart valve (THV)-the Myval THV-has been reported for ViV procedures. Here, we present a case-series of 5 patients, in whom tricuspid ViV procedure was performed using BE Myval THV, implanted supra-annularly by anchoring onto the deteriorated BHV. This case-series details the procedural steps to prevent in-hospital adverse events and early (30-day) mortality and the challenges during tricuspid ViV interventions.

Indexed as

balloon expandable heart valvesbioprosthetic heart valveMyval transcatheter heart valvetricuspid valvevalve-in-valve procedurevalvular heart disease

Identifiers

PMID37485262
PMCPMC10361752
OpenAlexW4383067048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.